A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer

• Published in: Zhongguo fei ai za zhi 2009-12, Vol.12 (12)
• Main Authors: WU, Yuhua, Hong, TAO, TANG, Junfang, ZHANG, Xinyong, ZHU, Yunzhong, LIU, Zhe, SHI, Heling, MENG, Qiyi, WU, Wei, LIU, Zan, GUO, Lili, LI, Mingzhi, XU, Liyan
• Format: Article
• Language: English
• Subjects: Clinical trials; Epidermal growth factor; Kinases; Lung cancer; Medical prognosis; Mutation
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/cjlc.v12i12.1071

背景与目的 厄洛替尼作为小分子EGFR酪氨酸激酶抑制剂，已经被多项国内外研究证明该药可延长非小细胞肺（non-small cell lung cancer, NSCLC）癌患者的中位无进展生存期和总生存期，并且这些生存优势在选择人群中更为明显。本研究回顾性总结了厄洛替尼在非选择NSCLC人群中的近期疗效及毒副反应，并初步观察了不同人群的疗效差异。方法 2005年7月-2009年7月之间应用厄洛替尼治疗的70例NSCLC病例，厄洛替尼每日口服1次，每次150 mg。服药4周后评价近期疗效及不良反应，以后每8周评价一次。结果 70例患者中68例可评价近期疗效，CR 0例，PR 26例，RR 38.2%，SD 24例，疾病控制率（DCR）73.5%，PD 18例（26.5%）。63例可评价中位无进展生存期（PFS），中位PFS 3.0个月。其中腺癌患者中位无进展生存期3.0个月，非腺癌患者为2.6个月，生存曲线存在统计学差异。非吸烟者的疗效高于吸烟者（51.7% vs 28.2%），差异有统计学意义（P=0.048）。毒副反应主要有腹泻、皮疹和ILD，ILD发生率达4.3%。结论 厄洛替尼治疗非小细胞肺癌有效，并且表现出对腺癌和非吸烟人群的选择性，未观察到性别差异。多数病人毒副反应可耐受。 Background and objective Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospectively oberserved the response, the survival and adverse reaction of erlotinib in non-selected non-small cell lung cancer. Methods The retrospective study included seventy non-small-cell lung cancer patients, who were treated with erlotinib from July 2005 to July 2009. Erlotinib was prescribed at a dose of 150 mg daily. Results Sixty-eight patients were evaluated response. Among these patients, CR 0 case, PR 26 cases, RR (CR+PR) 38.2% and SD 24 cases as their best response, disease control rate (DCR=CR+PR+SD) 73.5%, PD 18 cases (26.5%). Sixty-three patients were evaluated PFS. The median PFS was 3.0 months. The median PFS of adenocarcinoma and non-adenocarcinoma was 3.0 months vs 2.6 months. The drug-related adverse reactions were skin rash , diarrhea and interstitial lung disease (ILD)(4.3%). Conclusion Erlotinib is active in non-small cell lung cancer, and it is much more effective in adenocarcinoma and non-smoking patients. There is no difference in response or suvival concerning the sexuality. It is well tolerated in most patients.